Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nicotinamide riboside tartrate is a small molecule compound that serves as an orally active precursor to nicotinamide adenine dinucleotide (NAD+). As a salt form of nicotinamide riboside (a form of vitamin B3), it was developed by Biosynth Carbosynth as a more stable and manufacturable alternative to the chloride salt for large-scale production. The compound functions by increasing intracellular NAD+ levels, which in turn activates sirtuin enzymes such as SIRT1 and SIRT3. These enzymes are vital for mitochondrial health, oxidative metabolism, and cellular repair. It has been investigated for its potential therapeutic effects in metabolic abnormalities, high-fat diet-induced obesity, and neurodegenerative diseases like Alzheimer's disease. Currently, it is available as a research chemical and a dietary supplement.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nicotinamide riboside tartrate.